Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR…

Overview of attention for article published in BMC Medicine, January 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (58th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users
facebook: 1 Facebook page

reddit: 1 Redditor

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Facebook Reddit Dimensions citations

So far, Altmetric has seen 1 public wall post.

ALCASE Italia - Per la Lotta al Cancro del Polmone, 12 Jan 2023

Un nuovo inibitore EGFR di 3° generazione, il Rezivertinib (BPI-7711), appare particolarmente promettente in questo piccolo…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.